Compare ProShares UltraPro S&P500 (UPRO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro S&P500 vs GeneDx Holdings Corp — how do they compare? ProShares UltraPro S&P500 trades at $155.79 (market cap $5.55B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: ProShares UltraPro S&P500 is far larger — about 2.7× GeneDx Holdings Corp's market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro S&P500 for 29 Days and GeneDx Holdings Corp for 19 Days on average.
| UPRO | WGS | |
|---|---|---|
Market Cap | $5.55B | $2.02B |
Volume | 2,078,694 | 734,640 |
Sector | Leveraged / Inverse | Health |
52-Week High | $157.66 | $167.51 |
52-Week Low | $89.29 | $34.51 |
Typical Hold Time | 29 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UPRO trades at $155.78, up 0.37% today, with a bullish technical signal from moving averages and neutral oscillators. The stock faces resistance near $157 and support at $151. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. A dividend of $0.27 is scheduled for September 2026, indicating potential income for investors.
The outlook for UPRO is mixed, with technical strength offset by limited fundamental visibility. Risks include market volatility and concentration in top S&P 500 holdings. Upside depends on broader index performance, but investor skepticism amid high valuations may cap gains. Monitoring earnings growth and institutional sentiment is critical for direction.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
